Developer docs
API playgroundTry for free, no card

Search company profiles

Cosara Diagnostics

Full company profile

uuid000abtm

Namestring
Cosara Diagnostics
Legal namestring
Cosara Diagnostics Pvt. Ltd.
Websiteurl
cosara.in
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Cosara Diagnostics Pvt. Ltd. is an India-based joint venture incorporated in 2017 between Synbiotics Limited (Ambalal Sarabhai Enterprises) and Co-Diagnostics, Inc. (NASDAQ: CODX), headquartered in Ahmedabad with a 30,000 sq ft GMP manufacturing facility in Vadodara. The company manufactures in vitro molecular diagnostic products built on Co-Diagnostics' proprietary CoPrimer PCR technology, which is protected by US patents 10,093,966 and 10,704,087 and is claimed to deliver a 2.5 million-fold reduction in amplification errors relative to competing PCR methods. Its portfolio spans the SARAGENE real-time PCR kits (tuberculosis, HPV, hepatitis B/C, COVID-19, dengue, chikungunya, H1N1, malaria, drug-resistant TB), SARAPLEX multiplex kits, SARAQ viral load kits, SARAGENE Rapid card tests, and the Co-Dx Box / CoSara PCR Pro point-of-care instruments, covering 30+ pathogen targets across infectious disease and oncology-adjacent applications.

The company sells primarily through a network of regional distributors across South Asia (India, Bangladesh, Pakistan, Nepal, Sri Lanka) with direct enterprise sales into diagnostic chains, hospitals, and government health programs. Pricing is quote-based with multi-year institutional contracts, and the model combines one-time hardware sales (instruments, kits) with recurring reagent and cartridge revenue and CoPrimer technology licensing. Cosara holds ISO 13485:2016 certification for manufacturing and CDSCO approval for the CoSara PCR Pro instrument, and is pursuing Middle East and North Africa expansion through the CoMira Diagnostics joint venture with Arabian Eagle while exploring a SPAC transaction to fund further growth.

Short descriptiontext

Cosara Diagnostics is an India-based JV with Co-Diagnostics Inc. that manufactures IVD molecular diagnostic kits and point-of-care PCR instruments built on proprietary CoPrimer technology, serving hospitals, diagnostic chains, and government health programs across South Asia.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersAhmadabad, India
HQ citystring
Ahmadabad
HQ countrystring
India
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
molecular diagnostics, PCR test kits, rapid diagnostics, point-of-care testing, infectious disease testing
Industry2 codes
PRIMARYHLAAALAA
Molecular Diagnostics (PCR/qPCR, NGS-based assays)
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
NAICS code1 code
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
In Vitro Molecular Diagnostics
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Molecular Diagnostic Products
TypeHardware Sales
Description

Sale of molecular diagnostic kits and instruments including tuberculosis testing kits, multiplex PCR panels, and related reagents. One-time product sales model with repeat reagent orders.

2Point-of-Care Devices
TypeHardware Sales
Description

Sale of CoDx Box instruments and compatible test cartridges for point-of-care testing applications.

3Technology Licensing
TypeLicensing Royalties
Description

Licensing of CoPrimer technology to regional partners for manufacturing and distribution in specified territories.

Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Operations, Personnel, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure
Pricing details1 tier
1Enterprise/Institutional Pricing
ModelOne time/ perpetual licenseBilling cadenceMulti-year contract
Notes

Custom pricing based on volume, contract length, and customer type. Government and institutional pricing may vary.

GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 8 records shown
1SARAGENE®
Description

Real-Time PCR In Vitro Diagnostic Kits for various pathogens including MTB, Malaria, Hepatitis B/C, HPV, COVID-19, Chikungunya, Dengue, DRTB, and H1N1

+7 more records
Core offering1 text field

Cosara Diagnostics manufactures in vitro molecular diagnostic products under GMP at its Vadodara facility, including SARAGENE Real-Time PCR kits for infectious diseases (tuberculosis, malaria, hepatitis B/C, HPV, COVID-19, dengue, chikungunya, H1N1), SARAPLEX multiplex PCR kits, SARAQ viral load kits, SARAGENE Rapid card-based diagnostics, and PCR instruments (Co-Dx Box, CoSara PCR Pro). The offerings are powered by proprietary CoPrimer PCR technology licensed from Co-Diagnostics Inc. and are sold to hospitals, diagnostic chains, laboratories, and government health programs across South Asia.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Cosara Diagnostics offers a comprehensive molecular diagnostic portfolio centered on its proprietary CoPrimer® technology, which delivers 2.5 million times greater reduction in amplification errors than competing PCR technologies. The product ecosystem consists of four main product lines: (1) the Co-Dx Box™ System, a 48-reaction real-time PCR instrument platform; (2) SARAGENE® Real-Time PCR Kits covering 12 infectious disease tests including tuberculosis, malaria, hepatitis B/C, HPV, COVID-19, chikungunya, dengue, H1N1, and drug-resistant TB; (3) SARAPLEX® Real-Time PCR Multiplex Kits enabling simultaneous detection of multiple pathogens including flu/COVID-19, dengue-chikungunya, STI panel, and influenza differentiation; and (4) SARAQ® Real-Time PCR Viral Load Kits for quantitative HBV and HCV monitoring. Additionally, the company offers SARAGENE® Rapid Diagnostics card-based tests for point-of-care testing of HIV, hepatitis, syphilis, malaria, dengue, and typhoid. The CoPrimer technology enables mega multiplexing capabilities while virtually eliminating primer-dimers, the principal source of false positives in diagnostic testing.

Product and service6 records
1SARAGENE Real-Time PCR Kits
CategoryMolecular Diagnostics - PCR Kits
Description

Complete portfolio of real-time PCR in vitro diagnostic kits for infectious disease detection from respiratory, blood, cervical, and other clinical samples, sold to hospitals, diagnostic laboratories, and public health programs.

2SARAPLEX Real-Time PCR Multiplex Kits
CategoryMolecular Diagnostics - Multiplex PCR Kits
Description

Multiplex real-time PCR test kits enabling simultaneous detection and differentiation of multiple pathogens (Flu A/B + COVID-19, Dengue + Chikungunya, STI panel, Influenza subtypes) in a single reaction, sold to diagnostic laboratories.

3SARAQ Real-Time PCR Viral Load Kits
CategoryMolecular Diagnostics - Viral Load Kits
Description

Quantitative real-time PCR kits for viral load monitoring of Hepatitis B (HBV genotypes A-H) and Hepatitis C (HCV genotypes 1-6) from blood plasma/serum samples, validated against WHO International Standards, sold to diagnostic laboratories and clinical monitoring programs.

4SARAGENE Rapid Diagnostics Card Tests
CategoryRapid Diagnostics
Description

Card-based rapid immunochromatographic diagnostic tests for point-of-care detection of HIV (1/2), Hepatitis B Surface Antigen, HCV antibodies, Syphilis, Malaria pLDH/HRP II, Dengue NS1 antigen, Dengue NS1/IgG/IgM combo, and Typhoid IgG/IgM antibodies, sold to clinics, hospitals, and field screening programs.

5Co-Dx Box Real-Time PCR System
CategoryInstruments - Real-Time PCR System
Description

A 48-reaction real-time PCR system utilizing magnetic induction technology, designed for point-of-care molecular diagnostics with low maintenance requirements and easy-to-read results, sold to diagnostic laboratories, hospitals, and remote healthcare facilities.

6CoSara PCR Pro Instrument
CategoryInstruments - Point-of-Care PCR
Description

Point-of-care PCR instrument platform for molecular diagnostics, manufactured by Cosara under license from Co-Diagnostics Inc. for sale to diagnostic laboratories and healthcare institutions in India.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Joint venture partnership with Co-Diagnostics Inc. (NASDAQ: CODX) for the India market. Provides Cosara with access to Co-Diagnostics' proprietary CoPrimer technology, US manufacturing capabilities, and global technology validation. Cosara serves as exclusive licensee and manufacturer in India.

2Arabian Eagle
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Regional distribution partner for CoMira Diagnostics products in Saudi Arabia. Enables market expansion into the Middle East region through established local distribution network.

3Bio Molecular Systems
Strategic tierCoreTypeTechnology or Integration
Description

Manufacturing partner for CoDx Box point-of-care diagnostic device. Collaboration for production and supply of portable molecular diagnostic instruments.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global leader in molecular diagnostics with the GeneXpert system, dominant in TB (Xpert MTB/RIF) testing worldwide including India. Sets the benchmark Cosara's Co-Dx Box/PCR Pro must match in speed, footprint, and installed base.

TypeBroad incumbent
Description

Provides molecular sample preparation and PCR testing kits for infectious disease and HPV. Overlaps with Cosara's SARAGENE HPV and viral load kits and serves similar lab customers in South Asia.

TypeEmerging player
Description

Korean diagnostics company with strong presence in rapid point-of-care and molecular diagnostics for infectious diseases across emerging markets. Increasingly active in India and South Asia, competing on price-sensitive tenders similar to Cosara's government channel.

TypeBroad incumbent
Description

One of the largest diagnostics companies globally, with cobas systems for viral load (HBV/HCV/HIV), HPV, and infectious disease molecular testing. A high-end competitor with deep presence in Indian private hospital networks.

TypeDirect peer
Description

Indian molecular diagnostics company with the Truenat point-of-care PCR platform widely deployed for TB and other infectious disease testing across India and emerging markets. Closest direct competitor to Cosara in the same geography and same product categories (TB MTB, multiplex respiratory panels).

6Abbott Molecular
TypeBroad incumbent
Description

Broad molecular diagnostics portfolio (Alinity m, m2000) covering infectious disease, viral load, and HPV testing globally. Competes with Cosara in Indian hospital labs and large diagnostic chains on viral load (HBV/HCV) and HPV testing.

TypeDirect peer
Description

Indian diagnostics manufacturer with a broad molecular and rapid test portfolio across infectious diseases, including COVID-19, TB, HPV, and hepatitis. Competes directly with Cosara in India's hospital, lab, and government health channels.

TypeOthers
Description

Parent JV partner and CoPrimer technology licensor. Not a competitor but the closest relationship-of-record; its instrument roadmap (Co-Dx PCR Pro, sample prep instruments) determines Cosara's product cadence. Included for completeness as the upstream technology platform.

TypeBroad incumbent
Description

Panther/Panther Fusion molecular diagnostics platform used in labs for high-volume infectious disease and women's health testing. Competes with Cosara for HPV and infectious disease testing contracts at large Indian diagnostic chains.

TypeEmerging player
Description

South Korean molecular diagnostics company with the ExiStation and AccuPower PCR platforms for infectious disease testing. Comparable in scale and product positioning to Cosara's Co-Dx Box platform in emerging Asia.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cosara Diagnostics

In Vitro Molecular Diagnosticscosara.in

Cosara Diagnostics is an India-based JV with Co-Diagnostics Inc. that manufactures IVD molecular diagnostic kits and point-of-care PCR instruments built on proprietary CoPrimer technology, serving hospitals, diagnostic chains, and government health programs across South Asia.

What Cosara Diagnostics does

Cosara Diagnostics Pvt. Ltd. is an India-based joint venture incorporated in 2017 between Synbiotics Limited (Ambalal Sarabhai Enterprises) and Co-Diagnostics, Inc. (NASDAQ: CODX), headquartered in Ahmedabad with a 30,000 sq ft GMP manufacturing facility in Vadodara. The company manufactures in vitro molecular diagnostic products built on Co-Diagnostics' proprietary CoPrimer PCR technology, which is protected by US patents 10,093,966 and 10,704,087 and is claimed to deliver a 2.5 million-fold reduction in amplification errors relative to competing PCR methods. Its portfolio spans the SARAGENE real-time PCR kits (tuberculosis, HPV, hepatitis B/C, COVID-19, dengue, chikungunya, H1N1, malaria, drug-resistant TB), SARAPLEX multiplex kits, SARAQ viral load kits, SARAGENE Rapid card tests, and the Co-Dx Box / CoSara PCR Pro point-of-care instruments, covering 30+ pathogen targets across infectious disease and oncology-adjacent applications.

The company sells primarily through a network of regional distributors across South Asia (India, Bangladesh, Pakistan, Nepal, Sri Lanka) with direct enterprise sales into diagnostic chains, hospitals, and government health programs. Pricing is quote-based with multi-year institutional contracts, and the model combines one-time hardware sales (instruments, kits) with recurring reagent and cartridge revenue and CoPrimer technology licensing. Cosara holds ISO 13485:2016 certification for manufacturing and CDSCO approval for the CoSara PCR Pro instrument, and is pursuing Middle East and North Africa expansion through the CoMira Diagnostics joint venture with Arabian Eagle while exploring a SPAC transaction to fund further growth.

Cosara Diagnostics firmographics

Firmographics
Name
Cosara Diagnostics
Legal name
Cosara Diagnostics Pvt. Ltd.
Website
https://cosara.in
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Cosara Diagnostics is an India-based JV with Co-Diagnostics Inc. that manufactures IVD molecular diagnostic kits and point-of-care PCR instruments built on proprietary CoPrimer technology, serving hospitals, diagnostic chains, and government health programs across South Asia.
Ownership category
akta.pro rank

Cosara Diagnostics industry classification

Industry
Product category
In Vitro Molecular Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAALAA
Molecular Diagnostics (PCR/qPCR, NGS-based assays)
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)

Keywords

  • Molecular diagnostics
  • PCR test kits
  • Rapid diagnostics
  • Point-of-care testing
  • Infectious disease testing

Where Cosara Diagnostics is headquartered

Location

Headquarters

HQ city
Ahmadabad
HQ country
India
HQ region
Asia

Offices2 records

Markets served

Cosara Diagnostics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Personnel, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Molecular Diagnostic Products: Sale of molecular diagnostic kits and instruments including tuberculosis testing kits, multiplex PCR panels, and related reagents. One-time product sales model with repeat reagent orders.
  2. Point-of-Care Devices: Sale of CoDx Box instruments and compatible test cartridges for point-of-care testing applications.
  3. Technology Licensing: Licensing of CoPrimer technology to regional partners for manufacturing and distribution in specified territories.

Pricing tiers

ModelBillingPrice
One time/ perpetual licenseMulti-year contractEnterprise/Institutional Pricing

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Cosara Diagnostics product offering

Product offering

Core offering

Cosara Diagnostics manufactures in vitro molecular diagnostic products under GMP at its Vadodara facility, including SARAGENE Real-Time PCR kits for infectious diseases (tuberculosis, malaria, hepatitis B/C, HPV, COVID-19, dengue, chikungunya, H1N1), SARAPLEX multiplex PCR kits, SARAQ viral load kits, SARAGENE Rapid card-based diagnostics, and PCR instruments (Co-Dx Box, CoSara PCR Pro). The offerings are powered by proprietary CoPrimer PCR technology licensed from Co-Diagnostics Inc. and are sold to hospitals, diagnostic chains, laboratories, and government health programs across South Asia.

Product overview

Cosara Diagnostics offers a comprehensive molecular diagnostic portfolio centered on its proprietary CoPrimer® technology, which delivers 2.5 million times greater reduction in amplification errors than competing PCR technologies. The product ecosystem consists of four main product lines: (1) the Co-Dx Box™ System, a 48-reaction real-time PCR instrument platform; (2) SARAGENE® Real-Time PCR Kits covering 12 infectious disease tests including tuberculosis, malaria, hepatitis B/C, HPV, COVID-19, chikungunya, dengue, H1N1, and drug-resistant TB; (3) SARAPLEX® Real-Time PCR Multiplex Kits enabling simultaneous detection of multiple pathogens including flu/COVID-19, dengue-chikungunya, STI panel, and influenza differentiation; and (4) SARAQ® Real-Time PCR Viral Load Kits for quantitative HBV and HCV monitoring. Additionally, the company offers SARAGENE® Rapid Diagnostics card-based tests for point-of-care testing of HIV, hepatitis, syphilis, malaria, dengue, and typhoid. The CoPrimer technology enables mega multiplexing capabilities while virtually eliminating primer-dimers, the principal source of false positives in diagnostic testing.

Differentiator

Problem solved

Functional benefit

Brands

  • SARAGENE®: Real-Time PCR In Vitro Diagnostic Kits for various pathogens including MTB, Malaria, Hepatitis B/C, HPV, COVID-19, Chikungunya, Dengue, DRTB, and H1N1
  • SARAPLEX®
  • SARAQ®
  • SARAGENE® Rapid
  • Co-Dx Box™
  • CoSara PCR Pro®
  • SARAGENE® product line
  • Co-Dx™ PCR Platform

Products and services

  • SARAGENE Real-Time PCR Kits Complete portfolio of real-time PCR in vitro diagnostic kits for infectious disease detection from respiratory, blood, cervical, and other clinical samples, sold to hospitals, diagnostic laboratories, and public health programs.
  • SARAPLEX Real-Time PCR Multiplex Kits Multiplex real-time PCR test kits enabling simultaneous detection and differentiation of multiple pathogens (Flu A/B + COVID-19, Dengue + Chikungunya, STI panel, Influenza subtypes) in a single reaction, sold to diagnostic laboratories.
  • SARAQ Real-Time PCR Viral Load Kits Quantitative real-time PCR kits for viral load monitoring of Hepatitis B (HBV genotypes A-H) and Hepatitis C (HCV genotypes 1-6) from blood plasma/serum samples, validated against WHO International Standards, sold to diagnostic laboratories and clinical monitoring programs.
  • SARAGENE Rapid Diagnostics Card Tests Card-based rapid immunochromatographic diagnostic tests for point-of-care detection of HIV (1/2), Hepatitis B Surface Antigen, HCV antibodies, Syphilis, Malaria pLDH/HRP II, Dengue NS1 antigen, Dengue NS1/IgG/IgM combo, and Typhoid IgG/IgM antibodies, sold to clinics, hospitals, and field screening programs.
  • Co-Dx Box Real-Time PCR System A 48-reaction real-time PCR system utilizing magnetic induction technology, designed for point-of-care molecular diagnostics with low maintenance requirements and easy-to-read results, sold to diagnostic laboratories, hospitals, and remote healthcare facilities.
  • CoSara PCR Pro Instrument Point-of-care PCR instrument platform for molecular diagnostics, manufactured by Cosara under license from Co-Diagnostics Inc. for sale to diagnostic laboratories and healthcare institutions in India.

Companies that use Cosara Diagnostics

Customer profile

Named customers3 records

Segments2 records

Ideal customer profiles2 records

Cosara Diagnostics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Cosara Diagnostics partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered flagship and core.

  • Co-Diagnostics, Inc. (USA)flagshipStrategic or Co-development PartnerJoint venture partnership with Co-Diagnostics Inc. (NASDAQ: CODX) for the India market. Provides Cosara with access to Co-Diagnostics' proprietary CoPrimer technology, US manufacturing capabilities, and global technology validation. Cosara serves as exclusive licensee and manufacturer in India.
  • Arabian EaglecoreChannel Partner/ Reseller/ DistributorRegional distribution partner for CoMira Diagnostics products in Saudi Arabia. Enables market expansion into the Middle East region through established local distribution network.
  • Bio Molecular SystemscoreTechnology or IntegrationManufacturing partner for CoDx Box point-of-care diagnostic device. Collaboration for production and supply of portable molecular diagnostic instruments.

Scale indicators3 records

Recent moves8 records

Expansion highlights5 records

Cosara Diagnostics competitors and assessment

Company assessment

Broad incumbents

  • Cepheid (Danaher): Global leader in molecular diagnostics with the GeneXpert system, dominant in TB (Xpert MTB/RIF) testing worldwide including India. Sets the benchmark Cosara's Co-Dx Box/PCR Pro must match in speed, footprint, and installed base.
  • Qiagen: Provides molecular sample preparation and PCR testing kits for infectious disease and HPV. Overlaps with Cosara's SARAGENE HPV and viral load kits and serves similar lab customers in South Asia.
  • Roche Diagnostics: One of the largest diagnostics companies globally, with cobas systems for viral load (HBV/HCV/HIV), HPV, and infectious disease molecular testing. A high-end competitor with deep presence in Indian private hospital networks.
  • Abbott Molecular: Broad molecular diagnostics portfolio (Alinity m, m2000) covering infectious disease, viral load, and HPV testing globally. Competes with Cosara in Indian hospital labs and large diagnostic chains on viral load (HBV/HCV) and HPV testing.
  • Hologic: Panther/Panther Fusion molecular diagnostics platform used in labs for high-volume infectious disease and women's health testing. Competes with Cosara for HPV and infectious disease testing contracts at large Indian diagnostic chains.

Emerging players

  • SD Biosensor: Korean diagnostics company with strong presence in rapid point-of-care and molecular diagnostics for infectious diseases across emerging markets. Increasingly active in India and South Asia, competing on price-sensitive tenders similar to Cosara's government channel.
  • Bioneer: South Korean molecular diagnostics company with the ExiStation and AccuPower PCR platforms for infectious disease testing. Comparable in scale and product positioning to Cosara's Co-Dx Box platform in emerging Asia.

Direct peers

  • Molbio Diagnostics: Indian molecular diagnostics company with the Truenat point-of-care PCR platform widely deployed for TB and other infectious disease testing across India and emerging markets. Closest direct competitor to Cosara in the same geography and same product categories (TB MTB, multiplex respiratory panels).
  • Mylab Discovery Solutions: Indian diagnostics manufacturer with a broad molecular and rapid test portfolio across infectious diseases, including COVID-19, TB, HPV, and hepatitis. Competes directly with Cosara in India's hospital, lab, and government health channels.

Others

  • Co-Diagnostics (NASDAQ: CODX): Parent JV partner and CoPrimer technology licensor. Not a competitor but the closest relationship-of-record; its instrument roadmap (Co-Dx PCR Pro, sample prep instruments) determines Cosara's product cadence. Included for completeness as the upstream technology platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Cosara Diagnostics social profiles

Digital presence

Cosara Diagnostics compliance and trust

Trust signal

Compliance2 records

Cosara Diagnostics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cosara Diagnostics leadership team

Management profile

Number of profiles

Profiles5 records

Cosara Diagnostics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cosara Diagnostics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cosara Diagnostics

What does Cosara Diagnostics do?

Cosara Diagnostics manufactures in vitro molecular diagnostic products under GMP at its Vadodara facility, including SARAGENE Real-Time PCR kits for infectious diseases (tuberculosis, malaria, hepatitis B/C, HPV, COVID-19, dengue, chikungunya, H1N1), SARAPLEX multiplex PCR kits, SARAQ viral load kits, SARAGENE Rapid card-based diagnostics, and PCR instruments (Co-Dx Box, CoSara PCR Pro). The offerings are powered by proprietary CoPrimer PCR technology licensed from Co-Diagnostics Inc. and are sold to hospitals, diagnostic chains, laboratories, and government health programs across South Asia.

Is Cosara Diagnostics a public or private company?

Cosara Diagnostics is a private company. It is classified as corporate owned and is currently operating.

When was Cosara Diagnostics founded?

Cosara Diagnostics was founded in 2017. It employs 11 to 50 people.

Where is Cosara Diagnostics based?

Cosara Diagnostics is headquartered in Ahmadabad, India, in the Asia region.

How does Cosara Diagnostics make money?

Three revenue lines are on record. Molecular Diagnostic Products are the primary driver. The others are point-of-Care Devices and technology Licensing.

Who are Cosara Diagnostics's main competitors?

Broad incumbents on record are Cepheid (Danaher), Qiagen, Roche Diagnostics, Abbott Molecular and Hologic. Emerging players are SD Biosensor and Bioneer. Direct peers are Molbio Diagnostics and Mylab Discovery Solutions. Co-Diagnostics (NASDAQ: CODX) is listed as an others.

Does Cosara Diagnostics have an API?

No public API is recorded for Cosara Diagnostics.

What industry is Cosara Diagnostics in?

Cosara Diagnostics's product category is In Vitro Molecular Diagnostics. Its primary akta.pro industry code is HLAAALAA, Molecular Diagnostics (PCR/qPCR, NGS-based assays), with a secondary code of HLAAALAL, Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Investing.comCoSara submits tuberculosis test for India regulatory reviewCoSara Diagnostics submitted its PCR tuberculosis test to India's CDSCO for regulatory clearance. The test showed 97.3% sensitivity and 96% specificity across three batches. CoSara expects approval in Q4 2026 and plans to begin commercial sales in India before year-end.BioSpaceCo-Diagnostics Joint Venture CoSara Initiates Clinical Studies in India for Tuberculosis Test on PCR PlatformCo-Diagnostics' India joint venture CoSara is initiating clinical studies for a tuberculosis test on the CoSara PCR Pro instrument. The platform, using patented Co-Primers technology, delivers rapid real-time PCR results in about 30 minutes. The tests are expected to be manufactured and distributed in India under the CoSara brand.PR NewswireCo-Diagnostics Joint Venture CoSara Initiates Clinical Studies in India for Tuberculosis Test on PCR PlatformCo-Diagnostics, Inc. announced that its India joint venture CoSara Diagnostics has initiated clinical studies for a tuberculosis test using the Co-Dx PCR Pro instrument platform, with the equipment and test kits now deployed to select labs across India. The decentralized point-of-care platform uses patented Co-Primers technology to deliver real-time PCR results in approximately 30 minutes via a mobile application. India accounts for a significant share of the global tuberculosis burden, making it a strategically important market for expanding access to high-quality PCR testing in decentralized settings.TechbuzznewsCo-Diagnostics Bets the Future of PCR Is Not the Laboratory—It's EverywhereCo-Diagnostics completed clinical and analytical validation for its Co-Dx PCR Flu A/B & RSV test, targeting a U.S. FDA 510(k) submission in Q3 2026. The company also plans a CLIA Waiver by Application, aiming to deploy the handheld PCR platform in point-of-care settings. The platform is designed for decentralized use in pharmacies, clinics, and remote areas.BioSpaceCo-Diagnostics and CoSara Advance Ebola PCR Test Development and Co-Dx™ PCR Point-of-Care Platform CapabilitiesCo-Diagnostics, Inc. announced continued progress in its Ebola PCR development program with joint venture CoSara Diagnostics Pvt. Ltd., including a pan-Ebola assay and a multiplex assay designed to differentiate among Sudan, Taï Forest, Zaire, and Bundibugyo ebolaviruses. The blood-based Ebola assay would represent the first such test for the Co-Dx PCR Pro point-of-care platform, significantly expanding its capabilities beyond swab-based infectious disease testing. The dual-assay strategy is intended to support outbreak response and surveillance efforts in affected regions of Central Africa.PR NewswireCo-Diagnostics and CoSara Advance Ebola PCR Test Development and Co-Dx™ PCR Point-of-Care Platform CapabilitiesCo-Diagnostics, Inc. announced continued progress in its Ebola PCR development program with joint venture partner CoSara Diagnostics Pvt. Ltd., including both a pan-Ebola assay and a multiplex assay designed to detect and differentiate among Sudan, Taï Forest, Zaire, and Bundibugyo ebolavirus species. The blood-based assay under development would represent the first pathogen assay of its kind for the Co-Dx PCR Pro point-of-care platform, significantly expanding the platform's capabilities beyond swab-based infectious disease testing. The company stated this dual-assay strategy is intended to support outbreak response efforts, including potential partnerships with NGOs, subject to regulatory review and deployment requirements.Stock TitanCo-Diagnostics advances Ebola PCR test programCo-Diagnostics and CoSara are progressing in the development of Ebola PCR tests, including a dual-assay strategy for outbreak response and surveillance. The project involves creating tests capable of detecting and differentiating various Ebola strains, with potential application on the Co-Dx PCR platform which supports point-of-care testing.MarketBeatIs Co-Diagnostics National Security’s Next Diagnostic Pick?The WHO declared a PHEIC for the Bundibugyo virus Ebola outbreak, prompting nations to stockpile diagnostics. Co-Diagnostics, with joint ventures in India and Saudi Arabia, is advancing PCR assays for Ebola and tuberculosis, with a TB test commercial launch expected in Q3 2026. The company's stock rose over 200% in 30 days, and it seeks a SPAC listing for its Indian venture.Stock TitanCo-Diagnostics, CoSara advance Ebola PCR assay planCo-Diagnostics has advanced its PCR assay development strategy for the Bundibugyo virus (BDBV) causing an Ebola outbreak in the Democratic Republic of the Congo and Uganda, partnering with Indian joint venture CoSara Diagnostics to develop both BDBV-specific and pan-Ebola assay configurations. The WHO declared the outbreak a public health emergency of international concern on May 17, 2026, reporting over 900 suspected cases and 220 suspected deaths. The companies intend to leverage CoSara's regional manufacturing capabilities to support rapid deployment initiatives in international markets pending regulatory approvals.Investing.comEarnings call transcript: Co-Diagnostics Q4 2025 sees mixed results, stock up 12% By Investing.comCo-Diagnostics Inc. reported full-year 2025 revenue of $0.6 million, an 84.6% decline from 2024, alongside a net loss of $46.9 million increased from $37.6 million the prior year, primarily due to decreased grant revenue and a non-cash impairment charge of $18.9 million. Despite the significant earnings miss, the stock surged 12.12% to $2.59 as investors reacted positively to the company's strategic focus on platform development, including the Kodiak PCR platform and TB diagnostics targeting the Indian market. The company maintains four growth pillars—advancing its clinical pipeline, expanding CoSara operations in India with potential SPAC exploration, progressing the CoMira joint venture in Saudi Arabia for MENA manufacturing, and developing AI-driven capabilities.